Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T. Fukuokaya W, et al. Among authors: komura k. Int J Urol. 2024 Apr;31(4):342-347. doi: 10.1111/iju.15368. Epub 2023 Dec 19. Int J Urol. 2024. PMID: 38113343
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. Uchimoto T, et al. Among authors: komura k. Target Oncol. 2024 May;19(3):401-410. doi: 10.1007/s11523-024-01047-y. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546942
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Nishimura K, Takahara K, Saruta M, Fujita K, Hashimoto M, Uemura H, Shiroki R, Azuma T, Kimura T, Ohno Y. Hirasawa Y, et al. Among authors: komura k. J Cancer Res Clin Oncol. 2024 Apr 9;150(4):182. doi: 10.1007/s00432-024-05717-2. J Cancer Res Clin Oncol. 2024. PMID: 38592548 Free PMC article.
[Renal cell carcinoma in a horseshoe kidney: a case report].
Ibuki N, Uehara H, Komura K, Koyama K, Inamoto T, Segawa N, Tuji M, Azuma H, Katsuoka Y. Ibuki N, et al. Among authors: komura k. Hinyokika Kiyo. 2009 Oct;55(10):611-3. Hinyokika Kiyo. 2009. PMID: 19926945 Free article. Review. Japanese.
Can bladder preservation therapy come to the center stage?
Inamoto T, Ibuki N, Komura K, Juri H, Yamamoto K, Yamamoto K, Fujita K, Nonomura N, Narumi Y, Azuma H. Inamoto T, et al. Among authors: komura k. Int J Urol. 2018 Feb;25(2):134-140. doi: 10.1111/iju.13495. Epub 2017 Nov 23. Int J Urol. 2018. PMID: 29171098 Review.
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H. Inamoto T, et al. Among authors: komura k. Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018. Dis Markers. 2018. PMID: 30026881 Free PMC article.
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
Matsunaga T, Komura K, Hashimoto T, Muraoka R, Satake N, Tsutsumi T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Matsunaga T, et al. Among authors: komura k. World J Urol. 2020 Dec;38(12):3183-3190. doi: 10.1007/s00345-020-03118-x. Epub 2020 Feb 17. World J Urol. 2020. PMID: 32065276
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, Imai Y, Iwatani K, Ito K, Urabe F, Tsuzuki S, Kimura S, Terada N, Mukai S, Oyama Y, Abe H, Kamoto T, Azuma H, Miki J, Egawa S. Fukuokaya W, et al. Among authors: komura k. Urol Oncol. 2022 Jul;40(7):346.e1-346.e8. doi: 10.1016/j.urolonc.2022.02.020. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346571
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: komura k. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
298 results